GALLIUM研究:奥妥珠单抗或利妥昔单抗联合免疫化疗一线治疗滤泡性淋巴瘤——化疗方案对疗效与安全性的影响
GALLIUM研究纳入1202例既往未治疗的滤泡性淋巴瘤患者,随机1:1接受奥妥珠单抗(G)或利妥昔单抗(R)联合化疗(CHOP、CVP或苯达莫司汀,由中心非随机分配)。中位随访41.1个月,G联合化疗的无进展生存期(PFS)优于R联合化疗(总体HR 0.68,95%CI 0.54~0.87,P=0.0016),三种化疗方案结果一致;安全性谱因化疗方案而异,但比较受非随机化疗分配混杂。
要点
- G联合化疗较R联合化疗显著延长PFS(总体HR 0.68,95%CI 0.54~0.87,P=0.0016)
- 三种化疗方案中G的PFS获益一致:苯达莫司汀HR 0.63,CHOP HR 0.72,CVP HR 0.79
- 3~5级不良事件以CHOP最多见,3~5级感染和第二肿瘤以苯达莫司汀最多见
核心结论
- 在三种化疗方案中,G联合化疗均较R联合化疗改善PFS;安全性谱存在差异,但比较受非随机化疗分配混杂。
研究设计与样本
- GALLIUM研究(ClinicalTrials.gov注册号NCT01332968)为随机1:1对照研究,纳入1202例既往未治疗的滤泡性淋巴瘤(1~3a级)、晚期疾病(III或IV期,或II期且肿瘤直径≥7 cm)、ECOG体能状态0~2分且需要治疗的患者。
- 患者随机接受G 1000 mg(第1周期第1、8、15天及后续周期第1天)或R 375 mg/m2(每周期第1天),共6~8个周期,具体取决于化疗方案(由中心非随机分配);缓解者继续接受G或R治疗2年或直至疾病进展。
主要发现
- 中位随访41.1个月,G联合化疗的PFS(主要终点)优于R联合化疗(总体HR 0.68,95%CI 0.54~0.87,P=0.0016)。
- 各化疗方案结果一致:苯达莫司汀HR 0.63(95%CI 0.46~0.88),CHOP HR 0.72(95%CI 0.48~1.10),CVP HR 0.79(95%CI 0.42~1.47)。
- 3~5级不良事件(尤其是血细胞减少)以CHOP方案最常见。
- 3~5级感染和第二肿瘤以苯达莫司汀方案最常见,该方案与T细胞计数显著且持久的降低相关。
- 接受苯达莫司汀治疗的患者致死性事件更常见,可能反映患者风险特征的差异。
关键数值与推荐
- G联合化疗总体HR 0.68(95%CI 0.54~0.87,P=0.0016);苯达莫司汀HR 0.63(95%CI 0.46~0.88);CHOP HR 0.72(95%CI 0.48~1.10);CVP HR 0.79(95%CI 0.42~1.47)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 化疗方案由中心非随机分配,安全性比较受混杂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The GALLIUM study ( ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival (PFS) in previously untreated patients with follicular lymphoma relative to rituximab (R) when combined with cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P; CHOP); CVP; or bendamustine. This report focuses on the impact of chemotherapy backbone on efficacy and safety. Patients and Methods A total of 1,202 patients with previously untreated follicular lymphoma (grades 1 to 3a), advanced disease (stage III or IV, or stage II with tumor diameter ≥ 7 cm), Eastern Cooperative Oncology Group performance status 0 to 2, and requiring treatment were randomly assigned 1:1 to G 1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles or R 375 mg/m2 on day 1 of each cycle, for six to eight cycles, depending on chemotherapy (allocated nonrandomly by center). Responding patients received G or R for 2 years or until disease progression. Results Baseline Follicular Lymphoma International Prognostic Index risk, bulky disease, and comorbidities differed by chemotherapy. After 41.1 months median follow-up, PFS (primary end point) was superior for G plus chemotherapy (overall hazard ratio [HR], 0.68; 95% CI, 0.54 to 0.87; P = .0016), with consistent results across chemotherapy backbones (bendamustine: HR, 0.63; 95% CI, 0.46 to 0.88; CHOP: HR, 0.72; 95% CI, 0.48 to 1.10; CVP: HR, 0.79; 95% CI, 0.42 to 1.47). Grade 3 to 5 adverse events, notably cytopenias, were most frequent with CHOP. Grade 3 to 5 infections and second neoplasms were most frequent with bendamustine, which was associated with marked and prolonged reductions in T-cell counts. Fatal events were more frequent in patients treated with bendamustine, possibly reflecting differences in patient risk profiles. Conclusion Improved PFS was observed for G plus chemotherapy for all three chemotherapy backbones. Safety profiles differed, although comparisons are confounded by nonrandom chemotherapy allocation.
引用
- Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018. PMID: 29856692. doi:10.1200/JCO.2017.76.8960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。